BNGO Earnings Prediction
The chart below shows how BNGO performed 10 days before and after its earnings report, based on data from the past quarters. Typically, BNGO sees a +5.55% change in stock price 10 days leading up to the earnings, and a +3.40% change 10 days following the report. On the earnings day itself, the stock moves by -2.98%. This data can give you a slight idea of what to expect for the next quarter's release.
BNGO Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
6.07M
-34.83%
-21.85%
Gross Margin
-139.07%
-571.42%
-518.13%
Operating Margin
-372.58%
-3.38%
83.21%
Net Margin
-728.57%
-39.69%
248.97%
EPS
-0.52
-83.85%
116.67%
No Data Available
BNGO Earnings Analysis
Bionano Genomics, Inc. Common Stock Corporation (BNGO.O) Earnings Conference Call
Positive
Core Product Sales Performance: Revenue for Q3 2024 was $6.1 million, with $6.6 million in sales of core products and software, indicating strong performance in core offerings.
Installed Base Growth: The installed base of the OGMs grew to 368 systems during the quarter, representing a net increase of 67 systems year-over-year and a 22% growth over the installed base of 301 systems at the end of Q3 2023.
Flow Cell Sales Surge: Sales of flow cells in Q3 2024 reached 7,835 units, reflecting a 27% increase from the 6,176 flow cells sold in the same period last year.
Operating Cash Burn Reduction: The company reported a significant reduction in operating cash burn to approximately $14 million, a 46% decrease compared to approximately $26 million in the prior year.
Publication Growth Statistics: The total number of publications grew by 12% compared to the same period in 2023, with clinical research subjects covered in publications increasing by 82% from the same period last year.
Negative
Revenue Decline Analysis: Revenue decreased by 35% year-over-year, with a significant 29% reduction attributed to discontinued clinical services products.
Negative Gross Margin Decline: GAAP gross margin was negative at 139%, a stark decline from 30% in the same quarter of 2023, driven by $9.8 million in one-time charges.
Cash Burn Reduction: Operating cash burn was approximately $14 million, reflecting a 46% reduction compared to $26 million in the prior year, but still indicating ongoing financial strain.
Operating Expenses Reduction: Operating expenses for Q3 2024 were reported at $35.5 million, a 69% decrease from the previous year, yet still highlighting the need for further cost management.
Operating Expense Reductions: The company anticipates further reductions in operating expenses into 2025, indicating ongoing challenges in achieving profitability.
BNGO FAQs
How does BNGO typically perform around its earnings report dates?
Is Bionano Genomics, Inc. (BNGO) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
BNGO Earning Call Sentiment
Bionano Genomics, Inc. (BNGO) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
BNGO.O
-20.16%Positive
The earnings call reveals several concerning factors: a significant revenue decline, negative gross margins, and reduced guidance. Despite some positive developments like increased flow cell sales and cost reductions, the financial health remains weak. The Q&A section highlights uncertainty around product launches and growth potential, with management avoiding specific guidance. Additionally, registered direct offerings could dilute shareholder value. These factors suggest a likely negative stock price reaction over the next two weeks.